In March 2019, WHO issued “Consolidated guidelines on drug-resistant tuberculosis treatment”
Please find these via the link: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/
These consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB and replace all previous WHO guidelines on DR-TB. They include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and multidrug- and rifampicin-resistant (MDR/RR-TB), including longer and shorter regimens for MDR/RR-TB, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.
Also By
- Implementation of COVID-19 vaccination services in prison in six European countries: translating emergency intervention into routine life-course vaccination
- RISE-Vac - Co-Production of Vaccine Education Materials with Persons Living in Prison
- Interventions to increase vaccine uptake among people who live and work in prisons: A global multistage scoping review
Please Sign in (or Register) to view further.